Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
By Dr. Matthew Watson
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates.
Read the original post:
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
Related Post
- Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - March 31st, 2025
- HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - March 31st, 2025
- Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 31st, 2025
- Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors - March 31st, 2025
- Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - March 31st, 2025
- Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - March 31st, 2025
- HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress - March 31st, 2025
- Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension... - March 31st, 2025
- Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery... - March 31st, 2025
- Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 - March 31st, 2025
- Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - March 31st, 2025
- Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - March 31st, 2025
- First Three Children to Commence Treatment With Ryoncil® - March 31st, 2025
- BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office - March 31st, 2025
- Opthea Announces Decision to Discontinue Wet AMD Trials - March 31st, 2025
- Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the... - March 31st, 2025
- Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA - March 31st, 2025
- AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances - March 31st, 2025
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - March 31st, 2025
- Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - March 22nd, 2025
- FDA Approves New Prostate Cancer Imaging Agent Gozellix® - March 22nd, 2025
- OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category - March 22nd, 2025
- 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test - March 22nd, 2025
- Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - March 22nd, 2025
- Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 - March 22nd, 2025
- BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - March 22nd, 2025
- PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington - March 22nd, 2025
- Bright Green Corporation Announces the next steps for the completion of its restructuring plan - March 22nd, 2025
- Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million - March 22nd, 2025
- Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - March 22nd, 2025
- Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX - March 22nd, 2025
- Impact Biomedical Inc. Announcement Stock Activity/Pricing - March 22nd, 2025
- I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - March 22nd, 2025
- Better Choice Company Shareholders Overwhelmingly Approve Acquisition of SRx Health Solutions and Related Proposals - March 22nd, 2025
- Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - March 22nd, 2025
- Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting... - March 22nd, 2025
- Atea Pharmaceuticals Issues Statement Regarding Director Nominations - March 22nd, 2025
- Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - March 22nd, 2025
- Arialief Reviews (Is It Safe And Legit To Use?) What Do Arialief Consumer Reports Say About Its Efficacy? - March 22nd, 2025
- Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of... - March 11th, 2025
- BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System - March 11th, 2025
- PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands - March 11th, 2025
- Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 - March 11th, 2025
- Transactions under Novonesis’ share buyback program - March 11th, 2025
- Dogecoin Cash, Inc. ($CBDS) Expands into Meme Coin Market with Formation of MEME COINS Inc. - March 11th, 2025
- Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory... - March 11th, 2025
- Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO - March 11th, 2025
- MSInsight Announces €1.6 Million in Seed Fundraising to Revolutionize MSI Cancer Diagnosis - March 11th, 2025
- Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 - March 11th, 2025
- Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - March 11th, 2025
- Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - March 11th, 2025
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 11th, 2025
- Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update - March 11th, 2025
- CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies - March 11th, 2025
- Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs - March 11th, 2025
- Druid City Vital Care Recognized at Vital Care Infusion Services Annual Conference - March 11th, 2025
- Abpro Statement on the Departure of Former CEO Ian Chan - March 11th, 2025
- Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health... - March 11th, 2025
- ProstaVive Reviews (Consumer Report Analysis) Is It Safe And Effective For Healthy Prostate Function? - March 11th, 2025
- TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis - March 1st, 2025
- AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - March 1st, 2025
- Ultimovacs ASA: Approval and publication of prospectus - March 1st, 2025
- Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous... - March 1st, 2025
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - March 1st, 2025
- InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - March 1st, 2025
- Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting... - March 1st, 2025
- CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call - March 1st, 2025
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - March 1st, 2025
- ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting - March 1st, 2025
- SRx Health Solutions Granted Final Order to Proceed with the Acquisition by Better Choice Company - March 1st, 2025
- Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ® - March 1st, 2025
- Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older - March 1st, 2025
- Orion Corporation: Managers’ transactions – Outi Vaarala - March 1st, 2025
- Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination... - March 1st, 2025
- Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy - March 1st, 2025
- Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - March 1st, 2025
- 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - March 1st, 2025
- Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - March 1st, 2025
- Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - March 1st, 2025
- Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference - February 20th, 2025
Global News Feed
Comments Off on Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates |
March 31st, 2025
This author published 6132 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research